AAAAAA
Results: 26-50/56
Authors:
HELGASON AR
ADOLFSSON J
DICKMAN P
FREDRIKSON M
STEINECK G
Citation: Ar. Helgason et al., DISTRESS DUE TO UNWANTED SIDE-EFFECTS OF PROSTATE-CANCER TREATMENT ISRELATED TO IMPAIRED WELL-BEING (QUALITY-OF-LIFE), PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 128-133
Authors:
PENSON DF
LITWIN MS
LUBECK DP
FLANDERS S
PASTA DJ
CARROLL PR
Citation: Df. Penson et al., TRANSITIONS IN HEALTH-RELATED QUALITY-OF-LIFE DURING THE FIRST 9 MONTHS AFTER DIAGNOSIS WITH PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 134-143
Authors:
KRONGRAD A
LAI H
LAI S
Citation: A. Krongrad et al., DISEASE-SPECIFIC DEATH AFTER EXTERNAL-BEAM RADIATION OF PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 144-147
Authors:
GIOVANNUCCI E
KANTOFF P
SPIEGELMAN D
LOUGHLIN KR
WISHNOW KI
CORLESS C
MCDERMOTT A
WILLET WC
TALCOTT JA
Citation: E. Giovannucci et al., THE EPIDEMIC OF PROSTATE-CANCER AND THE MEDICAL LITERATURE - A CAUSALASSOCIATION, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 148-153
Authors:
KASHIF KM
FOLEY SJ
BASKETTER V
HOLMES SAV
Citation: Km. Kashif et al., HEMATURIA ASSOCIATED WITH BPH - NATURAL-HISTORY AND A NEW TREATMENT OPTION, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 154-156
Authors:
HAMMARSTEN J
HOGSTEDT B
HOLTHUIS N
MELLSTROM D
Citation: J. Hammarsten et al., COMPONENTS OF THE METABOLIC SYNDROME - RISK-FACTORS FOR THE DEVELOPMENT OF BENIGN PROSTATIC HYPERPLASIA, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 157-162
Authors:
KIRBY RS
CHAPPLE CR
SETHIA K
FLANNIGAN M
MILROY EJG
ABRAMS P
Citation: Rs. Kirby et al., MORNING VS EVENING DOSING WITH DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA - EFFICACY AND SAFETY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 163-171
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, NEOADJUVANT HORMONAL ABLATION ENHANCES THE RESULTS OF RADIOTHERAPY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, HOPE OF A NEW PROSTATE-CANCER VACCINE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-46
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, DR WALSH,PATRICK VISITS IRELAND, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, PROSTATE-CANCER CHARITABLE TRUST AWARD, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, 5 ALPHA-REDUCTASE INHIBITOR THERAPY REDUCES THE COMPLICATIONS OF BPH, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, WHATS IN THE PIPELINE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 46-46
Authors:
KIRBY R
SCHER H
BRAWER M
Citation: R. Kirby et al., UNTITLED, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 47-47
Authors:
SALOMON L
COLOMBEL M
PATARD JJ
GASMAN D
CHOPIN D
ABBOU CC
Citation: L. Salomon et al., PROSTATE BIOPSY IN THE STAGING OF PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 54-58
Authors:
ADOLFSSON J
Citation: J. Adolfsson, CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 59-65
Authors:
RONDINELLI RH
EPNER DE
TRICOLI JV
Citation: Rh. Rondinelli et al., INCREASED GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE-EXPRESSION INLATE PATHOLOGICAL STAGE HUMAN PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 66-72
Authors:
DEANTONI EP
GOKTAS S
STENNER J
ODONNELL C
CRAWFORD ED
Citation: Ep. Deantoni et al., A CROSS-SECTIONAL STUDY OF VASECTOMY, TIME SINCE VASECTOMY AND PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 73-78
Authors:
FENELEY MR
GREEN JSA
YOUNG MPA
BOSE P
KIRBY RS
PEELING WB
PARKINSON MC
Citation: Mr. Feneley et al., PREVALENCE OF PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN) IN BIOPSIES FROM HOSPITAL PRACTICE AND PILOT SCREENING - CLINICAL IMPLICATIONS, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 79-83
Authors:
KIRBY R
JARDIN A
Citation: R. Kirby et A. Jardin, DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - A REVIEWOF THE SAFETY PROFILE IN OLDER PATIENTS, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 84-89
Authors:
NIXON RG
WENER MH
SMITH KM
PARSON RE
BLASE AB
BRAWER MK
Citation: Rg. Nixon et al., DAY-TO-DAY CHANGES IN FREE AND TOTAL PSA - SIGNIFICANCE OF BIOLOGICALVARIATION, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 90-96
Authors:
LLOYD SN
KAVANAGH J
CHAN PSF
FERREIRA AM
GU FL
PAVONEMACALUSO M
XIA S
BLACKLOCK N
Citation: Sn. Lloyd et al., A MULTICENTER PROSPECTIVE-STUDY OF PROSTATIC VOLUME IN ASYMPTOMATIC MEN IN VARIOUS CONTINENTS, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 97-100
Authors:
KOCH MO
SMITH JA
Citation: Mo. Koch et Ja. Smith, LOW-MOLECULAR-WEIGHT HEPARIN AND RADICAL PROSTATECTOMY - A PROSPECTIVE ANALYSIS OF SAFETY AND SIDE-EFFECTS, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 101-104
Authors:
KIRBY R
SCHER H
BRAWER M
Citation: R. Kirby et al., UNTITLED, PROSTATE CANCER AND PROSTATIC DISEASES, 1(1), 1997, pp. 1-1
Authors:
KIRBY RS
Citation: Rs. Kirby, PRETREATMENT STAGING OF PROSTATE-CANCER - RECENT ADVANCES AND FUTURE-PROSPECTS, PROSTATE CANCER AND PROSTATIC DISEASES, 1(1), 1997, pp. 2-10